Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
13.35
+0.10 (0.75%)
At close: Mar 10, 2026, 4:00 PM EDT
13.44
+0.09 (0.67%)
After-hours: Mar 10, 2026, 6:06 PM EDT
Amneal Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts that cover Amneal Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $14.75, which forecasts a 10.49% increase in the stock price over the next year. The lowest target is $13 and the highest is $17.
Price Target: $14.75 (+10.49%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Amneal Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Buy | 3 | 3 | 4 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $15 → $17 | Strong Buy | Maintains | $15 → $17 | +27.34% | Mar 2, 2026 |
| Barclays | Barclays | Buy Initiates $15 | Buy | Initiates | $15 | +12.36% | Dec 9, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $11 → $13 | Buy | Reiterates | $11 → $13 | -2.62% | Oct 31, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $12 → $14 | Buy | Maintains | $12 → $14 | +4.87% | Sep 16, 2025 |
| Barclays | Barclays | Buy Maintains $10 → $11 | Buy | Maintains | $10 → $11 | -17.60% | Mar 3, 2025 |
Financial Forecast
Revenue This Year
3.21B
from 3.02B
Increased by 6.40%
Revenue Next Year
3.42B
from 3.21B
Increased by 6.54%
EPS This Year
0.98
from 0.22
Increased by 343.51%
EPS Next Year
1.18
from 0.98
Increased by 20.74%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 3.4B | 3.7B | |
| Avg | 3.2B | 3.4B | |
| Low | 3.0B | 3.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 11.4% | 14.2% | |
| Avg | 6.4% | 6.5% | |
| Low | 0.6% | -0.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.05 | 1.28 | |
| Avg | 0.98 | 1.18 | |
| Low | 0.85 | 1.09 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 377.3% | 31.3% | |
| Avg | 343.5% | 20.7% | |
| Low | 284.4% | 11.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.